| II-01 Khaled Abduljalil Impact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction Wednesday 15:35-17:00 |
| II-02 Tariq Abdulla Using Simcyp Designer to extend a PBPK-QSP Model of Warfarin to Target Binding Wednesday 15:35-17:00 |
| II-03 Oliver Ackaert Exposure Response Analysis of the Effect of Loperamide on the Cardiac Repolarization Interval in Healthy Adult Subjects Wednesday 15:35-17:00 |
| II-04 Eleni Alexopoulou Population pharmacokinetics of budesonide (BDS) and its two main metabolites 6β-hydroxy-budesonide(6OH-BDS) and 16α-hydroxy-prednisolone(16OH-PREDN) with and without hyperhydration effect Wednesday 15:35-17:00 |
| II-05 Mahmoud Ali Evaluation of the robustness of methods for model-based bioequivalence analysis for biosimilars: Clenoliximab as a case study Wednesday 15:35-17:00 |
| II-06 Simon Arsène In silico trials platform for exploration of trial design space in atopic dermatitis Wednesday 15:35-17:00 |
| II-07 Peter Ashcroft Mechanistic PKPD modelling of targeted protein degradation to improve compound selection in drug discovery and translation to the clinic Wednesday 15:35-17:00 |
| II-08 Rami Ayoun Alsoud Model-based interspecies scaling and impact of anti-drug antibodies on the pharmacokinetics of the therapeutic protein CB 4332 Wednesday 15:35-17:00 |
| II-09 Nicolas Azzopardi Mechanistic model of oxytocin/vasopressin-stimulated GPCR. Wednesday 15:35-17:00 |
| II-10 Dana Bakir Investigating Interoccasion Variability and Estimation Methods Wednesday 15:35-17:00 |
| II-11 Pavel Balazki 4ß-OH Cholesterol as endogenous biomarker for CYP3A4 inducer DDI studies – a PBPK-QSP platform for in silico compound testing Wednesday 15:35-17:00 |
| II-12 Catalina Barcelo Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis Wednesday 15:35-17:00 |
| II-13 Roberta Bartolucci Exposure-Response Analysis of the Macitentan Effects on NT-proBNP and WHO functional class in adult patients with Pulmonary Arterial Hypertension Wednesday 15:35-17:00 |
| II-14 Mattia Berton Physiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine Wednesday 15:35-17:00 |
| II-15 Sara Bettonte Onset and disappearance of induction on CYP3A4 and UGT1A1 substrates using PBPK modelling Wednesday 15:35-17:00 |
| II-16 Davide Bindellini Understanding the physiology of the hypothalamic-pituitary-adrenal axis to optimise cortisol replacement therapy: A quantitative modelling framework Wednesday 15:35-17:00 |
| II-17 Peter Bloomingdale An Artificial Intelligence Framework for Optimal Drug Design Wednesday 15:35-17:00 |
| II-18 Ivan Borisov An Algorithm to Generate Virtual Patients Cohort for a Model of Solid Tumor Treatment Wednesday 15:35-17:00 |
| II-19 Rolien Bosch Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R Agonist effects on glucose and body weight Wednesday 15:35-17:00 |
| II-20 Thomas Bouillon Comparison and selection of dosing regimens by discretization, optimizing efficacy and evaluating exposure demonstrated for KAE609 (Cipargamin) Wednesday 15:35-17:00 |
| II-21 THAM THI BUI Development of a physiological-based pharmacokinetic model for sacubitril and its metabolite Wednesday 15:35-17:00 |
| II-22 Núria Buil Bruna Understanding onset and extent of response using different clinical endpoints in Atopic Dermatitis Wednesday 15:35-17:00 |
| II-23 Elisa Calvier PBPK modelling of the DDI between a Drug X and gemfibrozil Wednesday 15:35-17:00 |
| II-24 Simona Catozzi Inter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin Wednesday 15:35-17:00 |
| II-25 Geraldine Celliere Comparison of a typical PK/PD model versus a mechanistic QSP model to predict the Phase II of a PSCK9 inhibitor, using MonolixSuite Wednesday 15:35-17:00 |
| II-26 JunSeok Cha A Pharmacokinetic/Pharmacodynamic Model of Recombinant Batroxobin Wednesday 15:35-17:00 |
| II-27 Marylore Chenel Physiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis Wednesday 15:35-17:00 |
| II-28 Wendy Chu Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa Wednesday 15:35-17:00 |
| II-29 Brian Cicali Long-acting formulation drug-drug interactions: evaluating the importance of timing using a subcutaneous levonorgestrel PBPK example Wednesday 15:35-17:00 |
| II-30 Michael Cloesmeijer Physiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen Wednesday 15:35-17:00 |
| II-31 Aude Coumau Population pharmacokinetic modelling to characterize (es)citalopram exposure in a large cohort of psychiatric patients Wednesday 15:35-17:00 |
| II-32 Jared Cui Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects Wednesday 15:35-17:00 |
| II-33 Marina Cuquerella Gilabert Title: Development of a Compartmental Advanced Physiologically based Dissolution, Absorption and Transit (CA-PhysDAT) model in PhysPK Wednesday 15:35-17:00 |
| II-34 Anna Dari Mechanistic Modeling Projections of Antibody Persistence After Homologous Booster Regimens of COVID-19 Vaccine Ad26.COV2.S in Humans Wednesday 15:35-17:00 |
| II-35 Pieter-Jan De Sutter Comparison of monoclonal antibody disposition predictions between different PBPK platforms Wednesday 15:35-17:00 |
| II-36 Wilbert de Witte Whole-body PBPK with tissue TMDD modelling to predict determining parameters of target occupancy in tissues Wednesday 15:35-17:00 |
| II-37 Neel Deferm Development of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer Wednesday 15:35-17:00 |
| II-38 Cleo Demeester Implementation of Oral Drug Absorption in Older Adults in the Physiologically Based Pharmacokinetic (PBPK) Modelling Platforms Wednesday 15:35-17:00 |
| II-39 Abdallah Derbalah Characterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model Wednesday 15:35-17:00 |
| II-40 Qian Dong Population pharmacokinetic analysis of nonlinear behavior of adefovir Wednesday 15:35-17:00 |
| II-41 Ilse Dubbelboer Lactation related milk volume changes: implementation in a PBPK cow model for oxytetracycline Wednesday 15:35-17:00 |
| II-42 Janna Duong A dermal physiologically-based pharmacokinetic (PBPK) model of clobetasol propionate to predict systemic exposure in eczema and dermatitis patients Wednesday 15:35-17:00 |
| II-43 Marwa Elhefnawy Quantifying the rate of blood glucose changes over the acute stage of ischemic stroke among patients with diabetes. Wednesday 15:35-17:00 |
| II-44 Jacqueline Ernest A translational site-of-action PK-PD modeling platform to propose treatment shortening regimens for tuberculosis Wednesday 15:35-17:00 |
| II-45 Edoardo Faggionato Assessing insulin sensitivity, glucose effectiveness, and β-cell responsivity using an integrated glucose, insulin, and C-peptide minimal model Wednesday 15:35-17:00 |
| II-46 Undine Falkenhagen Can quantitative systems pharmacology guide precision dosing? An illustrative warfarin-INR example Wednesday 15:35-17:00 |
| II-47 Alan Faraj A model for evaluation of novel on-demand treatment of bleeding events in hemophilia subjects Wednesday 15:35-17:00 |
| II-48 Anna Fochesato A minimal PBPK model to unveil anti-tuberculosis drug distribution in pulmonary lesions: a blueprint for improving efficacy screenings. Wednesday 15:35-17:00 |
| II-49 Sylvaine Galiegue Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies Wednesday 15:35-17:00 |
| II-50 María García-Cremades Risk stratification algorithm for MDR-TB patients based on pooled individual data analysis. Wednesday 15:35-17:00 |
| II-51 Maite Garraza Semi-mechanistic model of the Haemodynamic effects of propofol and remifentanil administered in combination to patients undergoing general anaesthesia Wednesday 15:35-17:00 |
| II-52 Frédéric Gaspar Population pharmacokinetics of apixaban in a real-life hospitalized population Wednesday 15:35-17:00 |
| II-53 Amira Ghoneim Modeling of the Pharmacokinetics of the Selective Orexin-1 Receptor Antagonist ACT-539313 with Auto-Inhibition Wednesday 15:35-17:00 |
| II-54 Audrick GIBERT PK/PD of unfractionned heparin during cardiopulmonary bypass: an individual patient data meta-analysis of two studies Wednesday 15:35-17:00 |
| II-55 Janice Goh A translational toolkit to predict clinical Phase IIb/III outcomes from preclinical mouse studies Wednesday 15:35-17:00 |
| II-56 Benjamin Guiastrennec Model-Based Translational Rapamycin Dose Selection to Promote Engraftment and Expansion of the Engineered Regulatory T cell (EngTreg) product GNTI-122 in Human Wednesday 15:35-17:00 |
| II-57 Berfin Gülave P-glycoprotein mediated drug-drug interaction at the blood-brain barrier on morphine brain distribution Wednesday 15:35-17:00 |
| II-58 Andrea Guzmán Individualized Tacrolimus dosing in pediatric kidney transplantation: identification of new genomic, proteomic and metabolomic biomarkers and PhysPK® development of PBPK-based predictive models, simulations and applications in different phamacogenomic subpopulations. Wednesday 15:35-17:00 |
| II-59 Sofia Guzzetti An integrated modelling approach for targeted degradation: insights on optimisation, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions Wednesday 15:35-17:00 |
| II-60 Chihiro Hasegawa Exploring simplification of a target-mediated drug disposition (TMDD) model for bispecific antibodies for potential application to data-driven modelling Wednesday 15:35-17:00 |
| II-61 Sara Carolina Henriques Development of a joint dissolution and pharmacokinetic model of propafenone and its hydroxylated metabolite Wednesday 15:35-17:00 |
| II-62 Yannick Hoffert An automated multi-model selection algorithm to improve precision dosing of tacrolimus in liver, lung, and bowel transplant recipients Wednesday 15:35-17:00 |
| II-63 Ana Homšek Population pharmacokinetic model of infliximab in patients with fistulising Crohn’s disease Wednesday 15:35-17:00 |
| II-64 Vincent Hurez Development of a primary Sjogren’s Syndrome (pSS) quantitative systems pharmacology (QSP) model linking mechanistic pathways to clinical scores. Wednesday 15:35-17:00 |
| II-65 Manuel Ibarra Enhancing the predictive accuracy of PBPK models for drug concentrations in tissues: accounting for the impact of relative distribution of blood flow Wednesday 15:35-17:00 |
| II-66 Vijay Ivaturi Novel convolution-based In vitro-In vivo correlation (IVIVC) model with time scaling and bioavailability sub-models for, JORNAY PM®, a methylphenidate hydrochloride delayed-release and extended-release capsule Wednesday 15:35-17:00 |
| II-67 Nattapon Jaisupa A physiologically-based pharmacokinetic model for prediction of cannabidiol pediatric dose Wednesday 15:35-17:00 |
| II-68 Masoud Jamei Application of a PBPK Model to Predict the Required Ceftazidime Concentration and Duration in Maternal and Umbilical Plasma Prior to Caesarean Section in Virtual Pregnant Women with Different Renal Function Wednesday 15:35-17:00 |
| II-69 SEONGMEE JEONG Human effective dose prediction of analgesic drug using translational PK-PD modeling Wednesday 15:35-17:00 |
| II-70 Woojin Jung Fractal kinetic implementation in population modeling Wednesday 15:35-17:00 |
| II-71 Soo-Min Jung Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Nesuparib (JPI-547) in Patients with Advanced Solid Tumor Wednesday 15:35-17:00 |
| II-72 Daniel Kaschek Joint modeling with Monolix using IQR Tools Wednesday 15:35-17:00 |
| II-73 Atefeh Kazeroonian A first-ever mechanistic disease model of IgG4-related disease identifies high-potential therapy targets Wednesday 15:35-17:00 |
| II-74 heungjo Kim Population pharmacokinetics of intravenous midazolam in critically ill patients supported with extracorporeal membrane oxygenation therapy Wednesday 15:35-17:00 |
| II-75 Bastian Kister Quantitative Systems Pharmacology of Interferon Alpha Administration and its induced cellular response in mice Wednesday 15:35-17:00 |
| II-76 Christine Juliane Kleist A PKPD model of favipiravir and ribavirin in Lassa virus infected mice Wednesday 15:35-17:00 |
| II-77 Niklas Korsbo DeepPumas for automatic discovery of individualizable functions governing longitudinal patient outcomes Wednesday 15:35-17:00 |
| II-78 Anis Krache Modelling selective cell targeting through avidity to inform bispecific antibody discovery and development Wednesday 15:35-17:00 |
| II-79 Hanna Kunina Blood glucose profile evaluation with model-based approach using continuous glucose monitoring data Wednesday 15:35-17:00 |
| II-80 Jialin Mao Shared Learning from a Physiologically-Based Pharmacokinetic Modeling Strategy for Human Pharmacokinetics Prediction through Retrospective Analysis of Genentech Compounds Wednesday 15:35-17:00 |
| II-81 Francois Mercier Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models Wednesday 15:35-17:00 |
| II-82 Andreas Noack On the error of the Laplace approximation when lags and duration parameters have between-subject variation Wednesday 15:35-17:00 |
| II-83 Rune Overgaard Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide Wednesday 15:35-17:00 |
| II-84 Teun Post Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population dose-hemoglobin model for Jesduvroq (daprodustat) Wednesday 15:35-17:00 |
| II-85 Mar Ribera I Armengol Application of Structural Identifiability Analysis and Parametrisation of a Linear Mixed Effects Mirabegron Model Wednesday 15:35-17:00 |
| II-86 Elena Righetti A mechanistic model of α-synuclein aggregation and degradation to bridge in vitro and in vivo research on Parkinson’s disease. Wednesday 15:35-17:00 |
| II-87 Sergio Sánchez Herrero Integrating Python optimization algorithms inside PhysPK® (PK/PD/PBPK) software for improving PK estimation methods. Wednesday 15:35-17:00 |
| II-88 Rajendra Singh A Time-to-event Modeling Approach Supporting the Safety Profile of New Deutetrabenazine (AUSTEDO) Titration Schemes in Patients with Tardive Dyskinesia and Huntington’s Disease Wednesday 15:35-17:00 |
| II-89 Nelleke Snelder From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. Wednesday 15:35-17:00 |
| II-90 Sara Soufsaf An Exploratory Analysis of the Performance of Methylphenidate Regimens Based on a PKPD Model of Dopamine and Norepinephrine Transporter Occupancy Wednesday 15:35-17:00 |
| II-91 Britta Steffens Enhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Graves’ disease under pharmacotherapy Wednesday 15:35-17:00 |
| II-92 Mohamed Tarek Marginal No-U-Turn Sampler for Bayesian Analysis in Pharmacometrics Wednesday 15:35-17:00 |
| II-93 Mohamed Tarek Fast cross-validation for Bayesian inference using proposals on a linear subspace Wednesday 15:35-17:00 |
| II-94 Franziska Thoma A fully hierarchical Bayesian approach to sequentially update population parameter uncertainty in MIPD Wednesday 15:35-17:00 |
| II-95 Monika Twarogowska A method to correct VPC bias due to non-random dropout via censored data addition, using the MonolixSuite Wednesday 15:35-17:00 |
| II-96 Martijn van Noort Two new user-friendly approaches to assess pharmacometric model identifiability Wednesday 15:35-17:00 |
| II-97 Yanlin Wang Development of a Population Pharmacokinetic Model to Describe the Pharmacokinetics of Aripiprazole 2-Month Ready-to-Use, a Novel Long-Acting Injectable Formulation of Aripiprazole for Administration Once Every 2 Months Wednesday 15:35-17:00 |
| II-98 Jen-Hao (Eric) Wu Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – results of study ITCC-059 Wednesday 15:35-17:00 |
